| Literature DB >> 33682583 |
Luis M de la Maza1, Toni L Darville2, Sukumar Pal1.
Abstract
INTRODUCTION: Chlamydia trachomatis is the most common sexually transmitted bacterial pathogen in the world. Antibiotic treatment does not prevent against reinfection and a vaccine is not yet available. AREAS COVERED: We focus the review on the progress made of our understanding of the immunological responses required for a vaccine to elicit protection, and on the antigens, adjuvants, routes of immunization and delivery systems that have been tested in animal models. PubMed and Google Scholar were used to search publication on these topics for the last 5 years and recent Reviews were examined. EXPERT OPINION: The first Phase 1 clinical trial of a C. trachomatis vaccine to protect against genital infections was successfully completed. We expect that, in the next five years, additional vaccine clinical trials will be implemented.Entities:
Keywords: Chlamydia muridarum; Chlamydia trachomatis; adjuvants; antigens; delivery systems; immunization; mouse model; routes of immunization; sexually transmitted infections; vaccines
Mesh:
Substances:
Year: 2021 PMID: 33682583 PMCID: PMC8934038 DOI: 10.1080/14760584.2021.1899817
Source DB: PubMed Journal: Expert Rev Vaccines ISSN: 1476-0584 Impact factor: 5.217